Reading AIFF? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AIFF free→Reading AIFF? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AIFF free→QuarterlyIQ Insights · AIFF
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On May 6, 2026, Firefly Neuroscience, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor up to 666,667 units (each a “Unit” and, collectively, the “Units”), at a purchase price of $1.50 per Unit, for aggregate gross proceeds of up to $1,000,000. Each Unit consists of (…
Unregistered Sales of Equity Securities. The information set forth under
Unregistered Sales of Equity Securities. The information set forth in
Entry into a Material Definitive Agreement. As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026 (the “Prior 8-K”), Firefly Neuroscience, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement, dated as of March 8, 2026 (the “Purchase Agreement”), with certain accredited investors (the “Initial Investors”), pursuant to which the Company agreed to issue and sell un…
Unregistered Sales of Equity Securities. The information set forth under
Entry into a Material Definitive Agreement. On March 8, 2026, Firefly Neuroscience, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (each an “Investor” and, collectively the “Investors”), pursuant to which the Company agreed to issue and sell up to 13,500,000 of units (each a “Unit” and, collectively the “Units”), at a purchase price of $1.50 per Unit. Pursuant to the Purchase Agreement, (i)…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 4, 2026, Firefly Neuroscience Ltd., a wholly-owned subsidiary of the Company, entered into an addendum (the “Addendum”) to the Personal Employment Agreement dated February 2, 2017, and a Contract Addendum dated June 21, 2021 (collectively, the “Existing Employment Agreement”), with Gil Issachar, the Company's Chief Technology Officer. T…
Entry into a Material Definitive Agreement. On February 3, 2026, Firefly Neuroscience, Inc., a Delaware corporation (the “Company”) entered into an At the Market Offering Agreement (the “ATM Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC (“KCP” or the “Sales Agent”), pursuant to which the Company may, from time to time, offer and sell shares of its common stock, par value $0.0001 per share, having an aggregate sales price of up to $7,434,266 (the “Sh…
Entry into a Material Definitive Agreement. On December 16, 2025, Firefly Neuroscience, Inc., a Delaware corporation (the “Company”), entered into a Warrants Cancellation and Exchange Agreement, dated as of December 16, 2025 (the “Warrant Exchange Agreement”) between the Company and each of certain investors (collectively, the “Warrant Investors”). The Warrant Exchange Agreement provides for (i) the surrender and cancellation of certain outstanding warrants previously issued to the Warrant In…
Unregistered Sales of Equity Securities. The information set forth in
Termination of a Material Definitive Agreement. As previously disclosed in the Current Report on Form 8-K filed by the Firefly Neuroscience, Inc. (the “Company”) on December 23, 2024, the Company entered into a purchase agreement (“ELOC Agreement”) with Arena Business Solutions Global SPC II, Ltd (“Arena”), dated December 20, 2024, pursuant to which Arena had committed to purchase, upon the terms and conditions specified in the ELOC Agreement, up to $10 million of the Company’s common stock,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 29, 2025, the Board of Directors (the “Board”) of the Company approved an amendment (the “Amendment”) to the employment agreement (the “Krzywicki Employment Agreement”), dated March 12, 2025, by and between Deel Canada Services Inc. (“Deel”), which provides consulting services to the Company, and Paul Krzywicki, the Chief Financial Office…
Unregistered Sales of Equity Securities. The information set forth under
Entry into a Material Definitive Agreement. On June 16, 2025, Firefly Neuroscience, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell $2,000,000 of units (each a “Unit” and, collectively the “Units”), at a purchase price of $3.00 per Unit. Each Unit consists of (i) either (A) one share of common stock, par value $0.0001…
Entry into a Material Definitive Agreement. On April 30, 2025, Firefly Neurosciences Inc., (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Evoke Neuroscience, Inc. (“Evoke”) and stockholders of Evoke (the “Sellers”), where the Sellers sold and the Company purchased all of the issued and outstanding shares of Evoke, for a total purchase price consisting of: (i) $3,000,000 in cash (the “Cash Purchase Price”); (ii) shares of the Company’s c…
Unregistered Sales of Equity Securities. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of David DeCaprio as the President and Chief Operating Officer On April 18, 2025, the Board of Directors (the “Board”) of Firefly Neuroscience, Inc. (the “Company”) appointed David DeCaprio (“DeCaprio”) as the President and Chief Operating Officer of the Company. On the same date, the Compensation Committee of the Board (the “Compensati…
Entry into a Material Definitive Agreement. Letter Agreements with BPY Limited and Nomis Bay Ltd. On January 9, 2025, the Board approved the issuance of an aggregate of 122,407 shares of the Company’s common stock, par value $0.0001 per share (“common stock”) to BPY Limited (“BPY”) and an aggregate of 217,593 shares of common stock to Nomis Bay Ltd. (“Nomis Bay”, together with BPY, the “Investors”), as an inducement for the Investors’ exercise of their respective Common Stock Purchase Warrant…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26, 2025, the board of directors of the Company (the “Board”) appointed Greg Lipschitz as the Chief Executive Officer of the Company. On March 27, 2025, the Board approved an Executive Employment Agreement with Greg Lipschitz, which was dated as of and entered into by the Company and Mr. Lipschitz on March 27, 2025 (the “Lipschitz Employme…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 10, 2025, Greg Lipschitz resigned from his position as the Executive Chairman of Firefly Neuroscience, Inc. (the “Company”), effective immediately. Mr. Lipschitz remains as a director of the Company. Mr. Lipschitz’s resignation was not related to any disagreement regarding the Company’s operations, policies or practices. On the same date,…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.